What is nOCD?
nOCD operates at the intersection of technology and clinical psychology, offering a specialized platform for individuals struggling with Obsessive-Compulsive Disorder. By facilitating live video sessions with licensed therapists trained in Exposure and Response Prevention (ERP), the company provides the gold standard of care in a digital-first format. This model addresses critical gaps in mental health accessibility, positioning nOCD as a vital infrastructure provider within the modern healthcare ecosystem. The company's focus on high-efficacy, evidence-based interventions has garnered significant attention from venture capital firms specializing in health-tech innovation.
How much funding has nOCD raised?
nOCD has raised a total of $80.2M across 5 funding rounds:
Private Equity
$1M
Debt
$150K
Series A
$12M
Series B
$33M
Other Financing Round
$34M
Private Equity (2017): $1M with participation from 7 Wire Ventures
Debt (2020): $150K led by PPP
Series A (2020): $12M supported by 7Wire Ventures, Chicago Ventures, Hyde Park Angels, and Meridian Street Capital
Series B (2021): $33M featuring F-Prime Capital Partners, Eight Roads, Chicago Ventures, Kaiser Permanente Ventures, 7wireVentures, and Health Enterprise Partners
Other Financing Round (2023): $34M backed by 7wireVentures, Health Enterprise Partners, Cigna Ventures, Eight Roads Capital, Kaiser Permanente Ventures, and Longitude Capital
Key Investors in nOCD
7wireVentures
7wire Ventures is a firm that builds and invests in early-stage digital health companies focused on creating informed and connected health consumers.
Health Enterprise Partners
HEP Fund partners with organizations transforming the healthcare industry to enhance healthcare delivery through a network of strategic payer and provider limited partners.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions companies to help innovators scale.
What's next for nOCD?
Following the latest capital infusion, nOCD is well-positioned to accelerate its product development and expand its clinical network. The strategic focus will likely center on enhancing the platform's technological capabilities, potentially integrating advanced data analytics to further personalize patient outcomes. As the company moves beyond its initial scaling phase, the emphasis will shift toward deepening integration with existing healthcare delivery systems and payers. This strategic evolution aims to cement nOCD's role as a cornerstone of digital mental health, ensuring that specialized ERP therapy remains a scalable and sustainable solution for patients globally.
See full nOCD company page
